DarioHealth Corp.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
DRIO$2.38-12.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Statements of Cash Flows (Unaudited)
U.S. dollars in thousands
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three months ended | ||||||
| · · March 31, | ||||||
| · · 2026 · · 2025 | ||||||
| Cash flows from operating activities: | | | | | | |
| Net loss | | $(8,249) | | $(9,227) | ||
| Adjustments required to reconcile net loss to net cash used in operating activities: | | | | | ||
| Stock-based compensation | | 1,441 | | 2,342 | ||
| Change in operating lease right of use assets | | 110 | | 110 | ||
| Amortization of acquired intangible assets | | 463 | | 1,162 | ||
| Depreciation and impairment | | 61 | | 94 | ||
| Change in fair value of warrant liability | | (177) | | (1,115) | ||
| Accrued interest on short term bank deposits | | | (21) | | | — |
| Non-cash financial expenses | | 159 | | 293 | ||
| Changes in operating assets and liabilities: | | | | | | |
| Decrease (increase) in trade receivables, net | | (75) | | 1,597 | ||
| Decrease (increase) in other accounts receivable, prepaid expense and long-term assets | | 269 | | (369) | ||
| Decrease in inventories | | 144 | | 130 | ||
| Increase (decrease) in trade payables | | 535 | | (300) | ||
| Decrease in other accounts payable and accrued expenses | | (341) | | (1,666) | ||
| Decrease in deferred revenues | | (213) | | (278) | ||
| Decrease in operating lease liabilities | | (116) | | (126) | ||
| Other | | (15) | | 680 | ||
| | | | | | | |
| Net cash used in operating activities | | (6,025) | | (6,673) | ||
| | | | | | | |
| Cash flows from investing activities: | | | | | ||
| Investment in short term bank deposit | | | (5,000) | | | — |
| Proceeds from maturity of short-term bank deposit | | | 4,200 | | | — |
| Purchase of property and equipment | | (31) | | (31) | ||
| Disposals of property and equipment | | | 5 | | | — |
| | | | | | | |
| Net cash used in investing activities | | (826) | | (31) | ||
| | | | | | | |
| Cash flows from financing activities: | | | | | ||
| Proceeds from issuance of preferred stock, net of issuance costs | | — | | 6,815 | ||
| | | | | | | |
| Net cash provided by financing activities | | — | | 6,815 | ||
| | | | | | | |
| Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents | | (6,851) | | 111 | ||
| Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash equivalents | | | 25 | | | (21) |
| Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | | 21,803 | | 27,764 | ||
| Cash, cash equivalents and restricted cash and cash equivalents at end of period | | $14,977 | | $27,854 | ||
| Supplemental disclosure of cash flow information: | | | | | ||
| Cash paid during the period for interest on long-term loan | | $965 | | $937 | ||
| Non-cash activities: | | | | | ||
| Exercise of pre-funded warrants to common stock | | $1,266 | | $1,750 | ||
| Deferred cost related to ATM offering | | $137 | | $— | ||
| Purchase of property and equipment on credit | | $5 | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.